Obesity Treatment Market: By Medicine Type (Centrally Acting Obesity Medicines, Peripherally Acting Obesity Medicines), By Mechanism of Action (Serotonin-Norepinephrine-Dopamine Reuptake Inhibitors (Sndris), Serotonin Reuptake Inhibitors, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics, Others), By Distribution Mode (Over-The-Counter Medicines, Prescription Medicines), By Route of Administration (Oral, Injectables), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Obesity Treatment Market size was valued at USD 752.6 million in 2022 and is poised to grow at a CAGR of 16.7% from 2023-2029. Obesity is a medical condition that occurs due to the excessive or abnormal accumulation of fat inside the body. Obesity is measured with respect to Basal Metabolic Index (BMI). According to the World Health Organization, more than 30 people are obese. Obesity may lead to osteoarthritis, cardiovascular diseases, diabetes, and various types of cancer. The risk factors for obesity include lack of physical exercise, excessive food intake, endocrine disorders, genetic inheritance, and due to some medications. Obesity treatment reduces body mass either by an increase in calorie consumption or by a decrease in craving. The global Obesity Treatment Market is expected to grow at a significant CAGR owing to an increase in the R&D activities for the innovation of new products and the presence of various pipeline products for the treatment of obesity. The increase in the prevalence of the obese population fuelling the obesity treatment market growth. According to the World Health Organization 2014, more than 39% of adults (600 Mn adults) adults and 42 Mn children were obese. In addition, the entry of generic products due to the patent expiry of blockbuster treatments also drives the revenue of obesity treatment. For instance, in March 2017, Novo Nordisk received European Commission marketing authorization approval for Saxenda an injectable obesity drug, and launched the same in the Indian market in 2017.

Obesity Treatment Market Key Developments:
  • In August 2017, Boehringer Ingelheim collaborated with Gubra for the development of obesity treatment
  • In March 2016, Orexigen Therapeutics Inc. inked an agreement with Takeda Pharmaceutical Company Ltd. to acquire U.S. rights to Contrave used in the treatment of obesity

Global Obesity Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

16.7%

Largest Market

North America

Fastest Growing Market

North America
Obesity Treatment Market Dynamics

Increase in the prevalence of obese population around the globe, increase in R&D activities for the innovation of new treatment, change in lifestyle such as food habits, and genetic inheritance is the major factors anticipated fuel the obesity treatment market over the forecast period. Moreover, increase in awareness about obesity treatment, huge pipeline products available for the obesity treatment, and government initiations for increasing awareness about chronic nature of obesity are propelling the obesity treatment market. However, high cost for R&D activities, alternative treatment for the obesity, adverse effects associated with the treatment, and stringent regulatory guidelines might hinder the growth of Obesity Treatment Market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Obesity Treatment Market Segmentation

By Action
  • Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs)
  • Serotonin reuptake inhibitors
  • Sympathomimetic-GABA receptor agonists
  • Sympathomimetics
  • Others
By Route Administration
  • Oral
  • Injectables
By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Frequently Asked Questions

The obesity treatment market is projected to expand at a CAGR of 16.7% during the forecast period

Boehringer Ingelheim GmbH, Novo Nordisk A/S, GlaxoSmithKline Plc, AstraZeneca Plc, F. Hoffmann La Roche Ltd.

North-America is the fastest-growing region for obesity treatment market

1.Executive Summary
2.Global Obesity Treatment Market Introduction 
2.1.Global Obesity Treatment Market  - Taxonomy
2.2.Global Obesity Treatment Market  - Definitions
2.2.1. By Action
2.2.2. By Route Administration
2.2.3. By Distribution Channel
2.2.4. By Region
3.Global Obesity Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Obesity Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Obesity Treatment Market  By Action, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs)
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Serotonin reuptake inhibitors
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Sympathomimetic-GABA receptor agonists
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Sympathomimetics
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Others
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
6.Global Obesity Treatment Market  By Route Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Oral
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Injectables
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Obesity Treatment Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Hospital pharmacies
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail pharmacies
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online pharmacies
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Obesity Treatment Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Obesity Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Action Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs)
9.1.2.Serotonin reuptake inhibitors
9.1.3.Sympathomimetic-GABA receptor agonists
9.1.4.Sympathomimetics
9.1.5.Others
9.2.  Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oral
9.2.2.Injectables
9.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital pharmacies
9.3.2.Retail pharmacies
9.3.3.Online pharmacies
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Obesity Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Action Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs)
10.1.2.Serotonin reuptake inhibitors
10.1.3.Sympathomimetic-GABA receptor agonists
10.1.4.Sympathomimetics
10.1.5.Others
10.2.  Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral
10.2.2.Injectables
10.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital pharmacies
10.3.2.Retail pharmacies
10.3.3.Online pharmacies
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Obesity Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Action Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs)
11.1.2.Serotonin reuptake inhibitors
11.1.3.Sympathomimetic-GABA receptor agonists
11.1.4.Sympathomimetics
11.1.5.Others
11.2.  Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral
11.2.2.Injectables
11.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital pharmacies
11.3.2.Retail pharmacies
11.3.3.Online pharmacies
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Obesity Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Action Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs)
12.1.2.Serotonin reuptake inhibitors
12.1.3.Sympathomimetic-GABA receptor agonists
12.1.4.Sympathomimetics
12.1.5.Others
12.2.  Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral
12.2.2.Injectables
12.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital pharmacies
12.3.2.Retail pharmacies
12.3.3.Online pharmacies
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Obesity Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Action Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs)
13.1.2.Serotonin reuptake inhibitors
13.1.3.Sympathomimetic-GABA receptor agonists
13.1.4.Sympathomimetics
13.1.5.Others
13.2.  Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral
13.2.2.Injectables
13.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital pharmacies
13.3.2.Retail pharmacies
13.3.3.Online pharmacies
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Boehringer Ingelheim GmbH (Germany)
14.2.2.Takeda Pharmaceuticals co. Ltd. (Japan)
14.2.3.Novo Nordisk A/S (Denmark)
14.2.4.GlaxoSmithKline Plc (U.K.)
14.2.5.AstraZeneca Plc (U.K.)
14.2.6.F. Hoffmann La Roche Ltd. (Switzerland)
14.2.8.Gubra (Denmark)
14.2.9.Orexigen Therapeutics Inc. (U.S.)
14.2.10.Eisai Co. Ltd. (Japan)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Boehringer Ingelheim GmbH (Germany)
  • Takeda Pharmaceuticals co. Ltd. (Japan)
  • Novo Nordisk A/S (Denmark)
  • GlaxoSmithKline Plc (U.K.)
  • AstraZeneca Plc (U.K.)
  • F. Hoffmann La Roche Ltd. (Switzerland)
  • Pfizer, Inc. (U.S.)
  • Gubra (Denmark)
  • Orexigen Therapeutics Inc. (U.S.)
  • Eisai Co. Ltd. (Japan)

Adjacent Markets